CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella, a biotechnology company pioneering transformative medicines for patients with severe conditions caused by disrupted amino acid biology, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will take place March 8, 2017 at 11:30 a.m. EST.
About Amino Acids
Beyond their role as building blocks of proteins, cell-specific sets of amino acids serve as regulators of central metabolism and critical biological pathways. Axcella has identified more than 2,000 diseases that are linked to amino acid imbalances for which cells alone cannot compensate. The Axcella team seeks to identify the optimal amino acid signature needed to re-establish amino acid homeostasis in dysregulated cells for each disease of focus.
Axcella is pioneering a revolutionary therapeutic modality that identifies how disturbances in amino acid biology lead to disease. The company’s platform rapidly yields novel molecules to restore normal amino acid homeostasis, treat disease and reactivate healthy central metabolism. Axcella has expeditiously translated its discoveries into molecules that have been tested in 10 clinical trials to date, with lead programs in intractable epilepsy, NASH and pathological atrophy. Its lead clinical candidates have demonstrated in human and preclinical models an ability to bring homeostasis to dysregulated cells, repair cellular function, restore healthy pathways, and regenerate tissue and healthy organ function. The company was founded by VentureLabs, the Innovation Foundry at Flagship Pioneering, and has received financing from Flagship’s venture funds, alongside co-investors Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.